Repurposing drugs in your medicine cabinet: Untapped opportunities for cancer therapy?

Future Oncology

Volumn 11, Issue 2, 2015, Pages 181-184

  Pantziarka, Pan ^a,b   Bouche, Gauthier ^a   Meheus, Lydie ^a   Sukhatme, Vidula ^c   Sukhatme, Vikas P ^c,d  

^a Anticancer Fund   (Belgium)

^b George Pantziarka TP53 Trust   (United Kingdom)

^c GlobalCures Inc   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

drug repurposing; health economics; health policy; off label drugs; ReDO Project

Indexed keywords

CIMETIDINE; CLARITHROMYCIN; DICLOFENAC; GLYCERYL TRINITRATE; ITRACONAZOLE; MEBENDAZOLE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER THERAPY; CLINICAL PRACTICE; COST UTILITY ANALYSIS; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG SAFETY; EVENT FREE SURVIVAL; HUMAN; INVESTMENT; LONG TERM CARE; MAXIMUM TOLERATED DOSE; NON PROFIT ORGANIZATION; ONCOLOGY; ORGANIZATION; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TUMOR MICROENVIRONMENT; DRUG APPROVAL; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG REPOSITIONING; HUMANS; NEOPLASMS;

EID: 84921362531     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.244     Document Type: Review

References (11)

1. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 16(24), 5972-5980 (2010).
2. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32(1), 40-51 (2014).
3. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 13(8), 790-801 (2012).
4. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673-683 (2004).
5. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 8, 442 (2014).
6. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing Drugs in Oncology (ReDO) - mebendazole as an anti-cancer agent. Ecancermedicalscience 8, 443 (2014).
7. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO) - cimetidine as an anti-cancer agent. Ecancermedicalscience 8, 445 (2014).
8. André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat. Rev. Clin. Oncol. 11(7), 413-431 (2014).
9. Sukhatme VP, Fang K, Lo A, Sukhatme V. Financial orphan therapies looking for adoption. Health Aff. (2014). http://healthaffairs.org
10. Sacher AG, Le LW, Leighl NB. Shifting patterns in the interpretation of Phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. J. Clin. Oncol. 32(14), 1407-1411 (2014).
11. Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst. Rev. 8(8), CD007814 (2012).